Evogene Ltd. income statement

In fiscal 2025, Evogene Ltd. reported revenue of $3.9m, down 30.9% on the year before, operating income of −$14.0m (a -364.2% margin) and net income of −$8.5m, or $1.08 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Evogene Ltd.: income statement, annual
Fiscal year	2015Dec 2015	2016Dec 2016	2017Dec 2017	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	11	7	3	2	1	1	1	2	3	6	4
Cost of revenue	8	6	3	1	0	1	1	1	1	2	4
Gross profit	3	1	1	0	0	0	0	1	1	3	−0
Research and development	14	16	17	15	16	17	21	21	16	13	8
Operating income	−18	−21	−22	−20	−21	−25	−31	−27	−22	−19	−14
Interest expense	—	—	—	—	0	0	0	0	0	0	0
Income before tax	−17	−20	−21	−21	−19	−26	−30	−30	−22	−15	−13
Income tax	—	0	0	0	0	0	0	0	0	0	0
Net income	−17	−20	−21	−21	−18	−23	−28	−27	−24	−16	−8
Diluted EPS	—	—	—	—	—	−$8.30	−$6.90	−$6.44	−$5.20	−$2.90	$1.08
Diluted shares (average)	3m	3m	3m	3m	3m	3m	4m	4m	5m	6m	8m
EBITDA	−17	−20	−22	−20	—	—	—	—	−22	−18	−14

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: DBVT vs EVGN DYAI vs EVGN ALGS vs EVGN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Evogene Ltd.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Evogene Ltd.